Investor Presentaiton
Pfizer Pipeline Highlights: TL1A and Anti-IFNẞ
TL1A: A monoclonal antibody for IBD with
potential for precision medicine
SCIENCE
A
•
TL1A amplifies cytokine production and
drives intestinal inflammation and fibrosis
Blocking TL1A potentially improves UC
disease pathology1
Anti-Interferon ẞ: A monoclonal antibody
with first-in-class potential for
dermatomyositis and more
•
IFN-ẞ protein levels elevated in patient blood³ and
mRNA levels increased in patient skin
Type 1 IFN-ẞ signature in blood and skin.
correlates with disease activity in skin
REASONS
TO BELIEVE
•
Promising endoscopic improvement in UC
patients in Phase 2a
Precision medicine approach utilizing key
biomarkers for patient selection may
enhance clinical outcomes
1. Clarke et al., 2018 mAbs; TL1Ai = Tumor Necrosis Factor-Like Cytokine 1A Inhibitor3; UC =
Ulcerative Colitis
Pfizer
•
•
.
Significant reduction in clinical disease activity
(CDASI) in skin observed in Phase 2
Reduction in IFN gene scores vs placebo
observed in Phase 2 study
ORPHAN (US/UK) & PRIME (EU) designations
granted
IFNb program in collaboration with Mass General Brigham; 2. Clearview Analysis; 3.
Liao et al, Ann Rheum Dis 70:831, 2011; 4. Huard et al. Br J Derm 176: 1224, 2017;
CDASI = Cutaneous Disease Area and Severity Index
13View entire presentation